Investigational drug · Phase 3
Marketed varicella vaccine
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chickenpox.
Phase 3Last checked: Nov 20, 2026Latest source record: May 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
9
Any phase or sponsor naming "Marketed varicella vaccine"
First trial start
2024
Nov 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Marketed varicella vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chickenpox
Largest trials
Live from ClinicalTrials.gov: studies naming "Marketed varicella vaccine" as an intervention, largest first.
Jiangsu Province Centers for Disease Control and PreventionResearch network
NCT07585370 · 24,740 participants (planned) · Start Mar 6, 2026 · Primary completion Jun 30, 2026
Drug: Attenuated Zoster Vaccine, Live; Matched Placebo Without Live Virus and 1 more · For: Herpes Zoster
Sites: Nanjing, China
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of AgePivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06740630 · 1,840 participants (planned) · Start Jan 10, 2025 · Primary completion Dec 25, 2026
Drug: Investigational varicella vaccine_Lot 1; Investigational varicella vaccine_Lot 2 and 8 more · For: Chickenpox
Sites: Mobile, Alabama; Hot Springs, Arkansas; Sherwood, Arkansas · 97 sites in all
- A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 YearsPivotal-lookingCompleted
Southeast University, ChinaAcademic, hospital or other
NCT06592456 · 1,200 participants · Start Jul 21, 2019 · Primary completion Oct 7, 2021
Drug: Chickenpox Vaccines · For: Chickenpox Vaccines
Sites: Huaian, China
- Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 YearsPivotal-lookingCompleted
Southeast University, ChinaAcademic, hospital or other
NCT06614816 · 1,200 participants · Start Feb 10, 2019 · Primary completion Jul 15, 2021
Drug: Oka strain varicella attenuated live vaccine · For: Chickenpox Vaccines
Sites: Huaian, China
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of AgePivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06855160 · 911 participants (planned) · Start Apr 17, 2025 · Primary completion Sep 10, 2026
Drug: Candidate varicella vaccine; Marketed varicella vaccine and 5 more · For: Chickenpox
Sites: Tucson, Arizona; Huntington Park, California; Sherman Oaks, California · 22 sites in all
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of AgePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05630846 · 801 participants · Start Dec 14, 2022 · Primary completion Jun 7, 2024
Drug: Investigational MMRV(H)NS vaccine; Investigational MM(H)RVNS vaccine and 2 more · For: Measles; Mumps; Rubella; Chickenpox; Measles
Sites: Birmingham, Alabama; Jonesboro, Arkansas; Bellflower, California · 47 sites in all
- A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of AgePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05084508 · 800 participants · Start Feb 3, 2022 · Primary completion Feb 9, 2024
Drug: Investigational varicella vaccine low potency; Investigational varicella vaccine medium potency and 6 more · For: Chickenpox
Sites: Bryant, Arkansas; Jonesboro, Arkansas; Little Rock, Arkansas · 51 sites in all
- A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgePivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06693895 · 750 participants (planned) · Start Nov 26, 2024 · Primary completion Nov 23, 2026
Drug: Investigational varicella vaccine; Marketed varicella vaccine and 5 more · For: Chickenpox
Sites: Phoenix, Arizona; Tucson, Arizona; Huntington Park, California · 46 sites in all
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of AgePivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06806137 · 600 participants (planned) · Start May 15, 2025 · Primary completion Dec 14, 2026
Drug: Investigational varicella vaccine; Marketed varicella vaccine and 5 more · For: Chickenpox
Sites: Salvaleón de Higüey, Dominican Republic; Constanza, Dominican Republic; Santo Domingo Oeste, Dominican Republic · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chickenpox
- MMR vaccinePhase 33 trials
GSK · Chickenpox
- Investigational varicella vaccinePhase 32 trials
GSK · Chickenpox
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.